Vol 26, No 6 (2021)
Research paper
Published online: 2021-08-13

open access

Page views 5935
Article views/downloads 246
Get Citation

Connect on Social Media

Connect on Social Media

Radiotherapy as treatment option in biliary cancer patients: a national survey of AIRO (Italian Association of Radiation Oncology) Gastroenterology Group

Valentina Lancellotta1, Mattia Falchetti Osti2, Giancarlo Mattiucci1, Alessio Morganti3, Vittorio Bini4, Cynthia Aristei5, Marco Lupattelli6
Rep Pract Oncol Radiother 2021;26(6):869-882.


Background: The aim is to find out how many radiation oncology centres treat biliary duct carcinoma (BDC), what treatments they offer and whether they would be interested in developing prospective trials.

Materials and methods: A questionnaire was posted to all 220 Italian Radiation Oncology Centres. The survey consisted of 31 eligibility questions in a combination of multiple and forced choice formats addressing the following parameters: characteristics of the centre, numbers of BDC patients treated, treatment options, radiotherapy parameters (target definition, schedule, technique, dose constraints) and interest in developing future randomized trials.

Results: No major differences emerged in BDC management, whatever the site, and whether it was resectable or not. Discrepancies in routine clinical practice were, however, observed with lack of agreement on expansion margins, dose constraints and treatment schedules for the stereotactic technique and palliative treatments.

Conclusions: The present survey attempted to fill the gaps in the role of radiotherapy in patients with BDC. Since lack of prospective randomized studies and disease rarity have mitigated against an evidence-based approach, patients with BDC should be enrolled in prospective studies. The above-mentioned results should also emphasize the need to combine analysis of treatment results from all Italian centres in order to create predictive models.

Article available in PDF format

View PDF Download PDF file


  1. DeOliveira M, Cunningham S, Cameron J, et al. Cholangiocarcinoma. Ann Surg. 2007; 245(5): 755–762.
  2. Miyakawa S, Ishihara S, Horiguchi A, et al. Biliary tract cancer treatment: 5,584 results from the Biliary Tract Cancer Statistics Registry from 1998 to 2004 in Japan. J Hepatobiliary Pancreat Surg. 2009; 16(1): 1–7.
  3. Park SW, Park YS, Chung JB, et al. Patterns and relevant factors of tumor recurrence for extrahepatic bile duct carcinoma after radical resection. Hepatogastroenterology. 2004; 51(60): 1612–1618.
  4. Horgan AM, Amir E, Walter T, et al. Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis. J Clin Oncol. 2012; 30(16): 1934–1940.
  5. Bonet Beltrán M, Roth AD, Mentha G, et al. Adjuvant radio-chemotherapy for extrahepatic biliary tract cancers. BMC Cancer. 2011; 11: 267.
  6. Hyder O, Dodson RM, Sachs T, et al. Impact of adjuvant external beam radiotherapy on survival in surgically resected gallbladder adenocarcinoma: a propensity score-matched Surveillance, Epidemiology, and End Results analysis. Surgery. 2014; 155(1): 85–93.
  7. Sahai P, Kumar S. External radiotherapy and brachytherapy in the management of extrahepatic and intrahepatic cholangiocarcinoma: available evidence. Br J Radiol. 2017; 90(1076): 20170061.
  8. Jackson MW, Amini A, Jones BL, et al. Treatment Selection and Survival Outcomes With and Without Radiation for Unresectable, Localized Intrahepatic Cholangiocarcinoma. Cancer J. 2016; 22(4): 237–242.
  9. Yoshioka Y, Ogawa K, Oikawa H, et al. Japanese Radiation Oncology Study Group (JROSG). Impact of intraluminal brachytherapy on survival outcome for radiation therapy for unresectable biliary tract cancer: a propensity-score matched-pair analysis. Int J Radiat Oncol Biol Phys. 2014; 89(4): 822–829.
  10. Bruha R, Petrtyl J, Kubecova M, et al. Intraluminal brachytherapy and selfexpandable stents in nonresectable biliary malignancies--the question of long-term palliation. Hepatogastroenterology. 2001; 48(39): 631–637.
  11. Kamada T, Saitou H, Takamura A, et al. The role of radiotherapy in the management of extrahepatic bile duct cancer: an analysis of 145 consecutive patients treated with intraluminal and/or external beam radiotherapy. Int J Radiat Oncol Biol Phys. 1996; 34(4): 767–774.
  12. Mahadevan A, Dagoglu N, Mancias J, et al. Stereotactic Body Radiotherapy (SBRT) for Intrahepatic and Hilar Cholangiocarcinoma. J Cancer. 2015;6:1099-104. 2015; 6(11): 1099–1104.
  13. Tao R, Krishnan S, Bhosale PR, et al. Ablative Radiotherapy Doses Lead to a Substantial Prolongation of Survival in Patients With Inoperable Intrahepatic Cholangiocarcinoma: A Retrospective Dose Response Analysis. J Clin Oncol. 2016; 34(3): 219–226.
  14. Lupattelli M, Osti MF, Agolli L, Lancellotta V. Vie biliari. in La Radioterapia dei Tumori Gastrointestinali: indicazioni e criteri guida. Gruppo di Studio AIRO per i tumori gastrointestinali 2014: 72–91.
  15. Associazione Italiana di Oncologia Medica (AIOM). Tumori delle vie biliari Edizione 2018. https://www.aiom.it/wp-content/uploads/2018/11/2018_LG_AIOM_VieBiliari.pdf (October 02, 2019).
  16. Valle JW JW, Borbath I. On behalf of the ESMO Guidelines Committee. Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016; 27(suppl 5): v28–v37.
  17. NCC (National Comprehensive Cancer Network). Clinical Practice Guidelines in OncologyTM. NCCN Guidelines for Treatment of Cancer by site. Clinical Practice Guidelines in Hepatobiliary Cancers. Version 1.2018. http://www.nccn.org/professionals/physician_gls/pdf/hepatobiliarycancer_blocks.pdf (October 02, 2019).
  18. Mattiucci GC, Autorino R, D’Agostino GR, et al. Chemoradiation and brachytherapy in extrahepatic bile duct carcinoma. Crit Rev Oncol Hematol. 2014; 90(1): 58–67.
  19. Xu X, Li J, Wu J, et al. A Systematic Review and Meta-analysis of Intraluminal Brachytherapy Versus Stent Alone in the Treatment of Malignant Obstructive Jaundice. Cardiovasc Intervent Radiol. 2018; 41(2): 206–217.
  20. Isohashi F, Ogawa K, Oikawa H, et al. Patterns of radiotherapy practice for biliary tract cancer in Japan: results of the Japanese radiation oncology study group (JROSG) survey. Radiat Oncol. 2013; 8: 76. 2013; 8(76).
  21. Shinohara ET, Mitra N, Guo M, et al. Radiation therapy is associated with improved survival in the adjuvant and definitive treatment of intrahepatic cholangiocarcinoma. Int J Radiat Oncol Biol Phys. 2008; 72(5): 1495–1501.
  22. Phelip JM, Vendrely V, Rostain F, et al. Gemcitabine plus cisplatin versus chemoradiotherapy in locally advanced biliary tract cancer: Fédération Francophone de Cancérologie Digestive 9902 phase II randomised study. Eur J Cancer. 2014; 50(17): 2975–2982.
  23. Barney BM, Olivier KR, Miller RC, et al. Clinical outcomes and toxicity using stereotactic body radiotherapy (SBRT) for advanced cholangiocarcinoma. Radiat Oncol. 2012; 7: 67.
  24. Weiner AA, Olsen J, Ma D, et al. Stereotactic body radiotherapy for primary hepatic malignancies - Report of a phase I/II institutional study. Radiother Oncol. 2016; 121(1): 79–85.
  25. Ben-Josef E, Guthrie KA, El-Khoueiry AB, et al. SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma. J Clin Oncol. 2015; 33(24): 2617–2622.
  26. Válek V, Kysela P, Kala Z, et al. Brachytherapy and percutaneous stenting in the treatment of cholangiocarcinoma: a prospective randomised study. Eur J Radiol. 2007; 62(2): 175–179.
  27. Shin HS, Seong J, Kim WC, et al. Combination of external beam irradiation and high-dose-rate intraluminal brachytherapy for inoperable carcinoma of the extrahepatic bile ducts. Int J Radiat Oncol Biol Phys. 2003; 57(1): 105–112.
  28. Zhu HD, Guo JH, Huang M, et al. Irradiation stents vs. conventional metal stents for unresectable malignant biliary obstruction: A multicenter trial. J Hepatol. 2018; 68(5): 970–977.
  29. Li WH, Luo JJ, Dai ZY, et al. Intraluminal brachytherapy combined with stent placement for the treatment of malignant obstructive jaundice. J Interv Radiol. 2015; 24: 215–8.
  30. Takada T, Amano H, Yasuda H, et al. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer. 2002; 95(8): 1685–1695.
  31. Neoptolemos JP, Moore MJ, Cox TF, et al. European Study Group for Pancreatic Cancer. Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. JAMA. 2012; 308(2): 147–156.
  32. Edeline J, Benabdelghani M, Bertaut A, et al. Gemcitabine and Oxaliplatin Chemotherapy or Surveillance in Resected Biliary Tract Cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): A Randomized Phase III Study. J Clin Oncol. 2019; 37(8): 658–667.
  33. Primrose J, Fox R, Palmer D, et al. Adjuvant capecitabine for biliary tract cancer: The BILCAP randomized study. J Clin Oncol. 2017; 35(15_suppl): 4006–4006.
  34. Lamarca A, Palmer DH, Wasan HS, et al. Advanced Biliary Cancer Working Group, ABC-02 Trial Investigators. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010; 362(14): 1273–1281.
  35. Henson CC, Davidson SE, Lalji A, et al. Gastrointestinal symptoms after pelvic radiotherapy: a national survey of gastroenterologists. Support Care Cancer. 2012; 20(9): 2129–2139.
  36. Tagliaferri L, Budrukkar A, Lenkowicz J, et al. ENT COBRA ONTOLOGY: the covariates classification system proposed by the Head & Neck and Skin GEC-ESTRO Working Group for interdisciplinary standardized data collection in head and neck patient cohorts treated with interventional radiotherapy (brachytherapy). J Contemp Brachytherapy. 2018; 10(3): 260–266.

Reports of Practical Oncology and Radiotherapy